BeiGene, Ltd., a global oncology-focused biopharma, announced FDA's fast-track approval for its cancer drug BRUKINSA(zanubrutinib).

Sodium bicarbonate, approved for medical use since 1981, continues to be a versatile treatment for many conditions.

Eli Lilly and Company announced that the FDA will convene its Advisory Committee to discuss Phase 3 results of the TRAILBLAZER-ALZ 2 study on the efficacy and safety of donanemab in early Alzheimer's.

In February, Amgen published a study in Nature Metabolism about AMG 133, a novel molecule with potential for treating obesity.

Regor Therapeutics Group has announced the launch of its Phase 2 trial on RGT-075, an oral, highly selective GLP-1 receptor agonist.

Triamcinolone, a synthetic corticosteroid, acts as a potent glucocorticoid receptor agonist, mainly used to treat autoimmune diseases such as psoriasis, lupus, and rheumatoid arthritis.

Amylyx Pharmaceuticals released initial results from their Phase 3 PHOENIX study, a 48-week global, randomized, double-blind, placebo-controlled trial, assessing AMX0035 in ALS patients.

Tharimmune revealed on their website plans to start a Phase 1 trial for TH104, assessing safety and bioavailability, with early results due Q2 2024.

VISEN Reveals China's Endorsement of Submission for the Biologic Drug License Concerning Lonapegsomatropin.

Nifedipine is a small molecule drug that acts as a blocker of voltage-dependent calcium channels (VDCCs), which are involved in the regulation of calcium ions in the cardiovascular system.

Akari Therapeutics and Peak Bio have reached a final merger agreement, positioning themselves as partners to develop a broader portfolio with an innovative Antibody Drug Conjugate (ADC) technology base.

In February, University of Leicester and Leicester Diabetes Centre experts published a summary of obesity treatments in "International Journal of Obesity," highlighting new drugs inspired by gut incretin hormones.